Osteonecrosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OST003 MIFTS: 63	Osteonecrosis Categories: Bone diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Osteonecrosis

MalaCards integrated aliases for Osteonecrosis:

Name: Osteonecrosis ³⁸ ¹² ⁷⁶ ⁴³ ⁴⁴ ¹⁵

Bone Necrosis ¹² ⁷³

Avascular Necrosis of Bone ¹²

Classifications:

MalaCards categories:
Anatomical: Bone diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the musculoskeletal system and connective tissue

Other osteopathies

Osteonecrosis

Osteonecrosis due to drugs

Osteonecrosis due to previous trauma

Osteonecrosis, unspecified

Osteopathies in diseases classified elsewhere

Osteonecrosis due to haemoglobinopathy

Osteonecrosis in other diseases classified elsewhere

External Ids:

Disease Ontology ¹² DOID:10159

ICD10 ³³ M87 M87.9 M87.1 more

ICD9CM ³⁵ 732.3 733.41 733.42 more

MeSH ⁴⁴ D010020

NCIt ⁵⁰ C34404 C34841 C34880 more

SNOMED-CT ⁶⁸ 156837008 17926002 203487006 more

UMLS ⁷³ C0003977 C0027543 C0029445 more

Sources

Summaries for Osteonecrosis

MedlinePlus : ⁴³ Osteonecrosis is a disease caused by reduced blood flow to bones in the joints. In people with healthy bones, new bone is always replacing old bone. In osteonecrosis, the lack of blood causes the bone to break down faster than the body can make enough new bone. The bone starts to die and may break down. You can have osteonecrosis in one or several bones. It is most common in the upper leg. Other common sites are your upper arm and your knees, shoulders and ankles. The disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties. At first, you might not have any symptoms. As the disease gets worse, you will probably have joint pain that becomes more severe. You may not be able to bend or move the affected joint very well. No one is sure what causes the disease. Risk factors include Long-term steroid treatment Alcohol abuse Joint injuries Having certain diseases, including arthritis and cancer Doctors use imaging tests and other tests to diagnose osteonecrosis. Treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteonecrosis, also known as bone necrosis, is related to osteonecrosis of the jaw and legg-calve-perthes disease, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Osteonecrosis is BMP2 (Bone Morphogenetic Protein 2), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and Rheumatoid arthritis. The drugs Alendronate and Zoledronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, bone and bone marrow, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : ¹² An ischemic bone disease that results in necrosis located in bone.

Wikipedia : ⁷⁶ Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to... more...

Sources

Related Diseases for Osteonecrosis

Diseases related to Osteonecrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)

#	Related Disease	Score	Top Affiliating Genes
1	osteonecrosis of the jaw	33.8	CYP2C8 FDPS VEGFA
2	legg-calve-perthes disease	32.6	COL2A1 SERPINC1 SERPINE1
3	thrombophilia	30.5	F2 MTHFR SERPINC1 SERPINE1
4	osteoporotic fracture	30.5	MTHFR TNFRSF11B
5	myeloma, multiple	30.4	ABCB1 TNFRSF11B TNFSF11 VEGFA
6	disseminated intravascular coagulation	30.3	F2 SERPINC1 SERPINE1
7	protein s deficiency	30.3	F2 MTHFR SERPINC1
8	kummell's disease	30.3	TNFRSF11B TNFSF11
9	antithrombin iii deficiency	30.1	F2 MTHFR SERPINC1
10	osteomyelitis	30.1	ACP5 BMP2 TNFSF11
11	protein c deficiency	30.1	F2 MTHFR SERPINC1
12	villonodular synovitis	30.0	ACP5 TNFSF11
13	giant cell tumor	29.7	BGLAP TNFRSF11B TNFSF11
14	periodontitis	29.7	BGLAP RUNX2 TNFRSF11B TNFSF11
15	renal osteodystrophy	29.5	BGLAP PTH TNFRSF11B
16	vascular disease	28.9	F2 MTHFR SERPINC1 SERPINE1 TNFRSF11B VEGFA
17	paget's disease of bone	27.5	ACP5 BGLAP PTH TNFRSF11B TNFSF11
18	glucocorticoid-induced osteoporosis	26.3	ACP5 BGLAP BMP2 PTH RUNX2 TNFRSF11B
19	bone disease	25.6	ACP5 BGLAP BMP7 COL2A1 PTH RUNX2
20	osteoporosis	25.0	ACP5 BGLAP BMP2 COL2A1 CYP3A4 FDPS
21	dysbaric osteonecrosis	12.3
22	avascular necrosis of femoral head, primary, 1	11.6
23	familial avascular necrosis of the femoral head	11.4
24	freiberg's disease	11.2
25	inferior vena cava interruption	11.0	MTHFR SERPINE1
26	neonatal stroke	10.9	MTHFR SERPINE1
27	amaurosis fugax	10.9	MTHFR SERPINE1
28	hemifacial spasm	10.9	MTHFR VEGFA
29	mesenteric vascular occlusion	10.9	F2 MTHFR
30	thiemann disease	10.9
31	gaucher disease, type iii	10.9
32	kienbock's disease	10.9
33	livedoid vasculopathy	10.8	F2 MTHFR SERPINE1
34	fibrinolytic defect	10.8	SERPINC1 SERPINE1
35	cryptogenic cirrhosis	10.7	F2 MTHFR SERPINE1
36	buerger disease	10.7	F2 MTHFR SERPINE1
37	mucositis	10.7	ABCB1 MTHFR VEGFA
38	intestinal impaction	10.7	F2 SERPINC1
39	fournier gangrene	10.7	F2 SERPINC1
40	polyarticular onset juvenile idiopathic arthritis	10.6	TNFRSF11B TNFSF11
41	nutritional deficiency disease	10.6	BGLAP F2 MTHFR
42	argentine hemorrhagic fever	10.6	SERPINC1 SERPINE1
43	ischemic neuropathy	10.6	F2 MTHFR
44	spinal cord infarction	10.6	F2 MTHFR SERPINC1
45	sudden sensorineural hearing loss	10.6	F2 MTHFR SERPINC1
46	blood protein disease	10.6	F2 MTHFR SERPINC1
47	hemangioma of liver	10.6	CYP3A4 F2
48	sticky platelet syndrome	10.6	SERPINC1 SERPINE1
49	osteopetrosis, autosomal dominant 2	10.6	BGLAP TNFSF11
50	marantic endocarditis	10.6	F2 MTHFR SERPINC1

Graphical network of the top 20 diseases related to Osteonecrosis:

Sources

Symptoms & Phenotypes for Osteonecrosis

UMLS symptoms related to Osteonecrosis:

back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Osteonecrosis:

⁴⁶ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.25	BMP7 ABCB1 COL2A1 BMP2 F2 SERPINC1
2	growth/size/body region	MP:0005378	10.23	BMP2 F2 MTHFR BMP7 ABCB1 COL2A1
3	hematopoietic system	MP:0005397	10.17	BMP2 F2 BMP7 ABCB1 RUNX2 TNFSF11
4	immune system	MP:0005387	10.15	F2 BMP7 ABCB1 COL2A1 BMP2 TNFSF11
5	homeostasis/metabolism	MP:0005376	10.14	BMP2 F2 MTHFR ABCB1 COL2A1 RUNX2
6	craniofacial	MP:0005382	10.1	BMP7 COL2A1 BMP2 RUNX2 TNFSF11 PTH
7	mortality/aging	MP:0010768	10.07	BMP2 F2 MTHFR BMP7 ABCB1 COL2A1
8	digestive/alimentary	MP:0005381	10.02	BMP2 F2 BMP7 ABCB1 COL2A1 RUNX2
9	limbs/digits/tail	MP:0005371	9.97	BMP7 MTHFR COL2A1 BMP2 TNFSF11 VEGFA
10	reproductive system	MP:0005389	9.81	BMP2 F2 MTHFR BMP7 ABCB1 RUNX2
11	respiratory system	MP:0005388	9.5	F2 BMP7 COL2A1 RUNX2 TNFSF11 SERPINE1
12	skeleton	MP:0005390	9.32	F2 BMP7 MTHFR COL2A1 BMP2 TNFSF11

Sources

Drugs & Therapeutics for Osteonecrosis

Drugs for Osteonecrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Alendronate

Approved

Phase 4,Phase 2,Phase 1

121268-17-5, 66376-36-1

2088

Zoledronic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

118072-93-8

68740

Pentoxifylline

Approved, Investigational

Phase 4,Phase 3

6493-05-6

4740

Dalteparin

Approved

Phase 4

9005-49-6

Enoxaparin

Approved

Phase 4

9005-49-6

772

Heparin

Approved, Investigational

Phase 4

9005-49-6

772 46507594

Rivaroxaban

Approved

Phase 4

366789-02-8

Hyaluronic acid

Approved, Vet_approved

Phase 4

9004-61-9

53477741

Tocopherol

Approved, Investigational, Nutraceutical

Phase 4,Phase 3

1406-66-2

14986

Vitamin E

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3

59-02-9

14985

Serine

Approved, Nutraceutical

Phase 4

56-45-1

5951

Bone Density Conservation Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Diphosphonates

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anesthetics

Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable

Antioxidants

Phase 4,Phase 3

Micronutrients

Phase 4,Phase 3,Phase 2

Phosphodiesterase Inhibitors

Phase 4,Phase 3

Platelet Aggregation Inhibitors

Phase 4,Phase 3

Protective Agents

Phase 4,Phase 3

Radiation-Protective Agents

Phase 4,Phase 3

Tocopherols

Phase 4,Phase 3

Tocotrienols

Phase 4,Phase 3

Trace Elements

Phase 4,Phase 3,Phase 2

Vasodilator Agents

Phase 4,Phase 3

Vitamins

Phase 4,Phase 3,Phase 2,Phase 1

Anticoagulants

Phase 4

Antithrombin III

Phase 4

Antithrombins

Phase 4

calcium heparin

Phase 4

Factor Xa Inhibitors

Phase 4

Heparin, Low-Molecular-Weight

Phase 4

HIV Protease Inhibitors

Phase 4

protease inhibitors

Phase 4

Serine Proteinase Inhibitors

Phase 4

Pharmaceutical Solutions

Phase 4,Not Applicable

Ferrosoferric Oxide

Phase 4,Not Applicable

Hematinics

Phase 4,Not Applicable

Parenteral Nutrition Solutions

Phase 4,Not Applicable

Adjuvants, Immunologic

Phase 4

Viscosupplements

Phase 4

Tocotrienol

Investigational, Nutraceutical

Phase 4,Phase 3

6829-55-6

Etoposide

Approved

Phase 3

33419-42-0

36462

Fludarabine

Approved

Phase 3

21679-14-1, 75607-67-9

30751

Thiotepa

Approved, Investigational

Phase 3

52-24-4

5453

Denosumab

Approved

Phase 3,Phase 1,Phase 2

615258-40-7

Docetaxel

Approved, Investigational

Phase 3,Phase 2

114977-28-5

148124

Gemcitabine

Approved

Phase 3

95058-81-4

60750

Prednisone

Approved, Vet_approved

Phase 3,Phase 2,Not Applicable

53-03-2

5865

Acetylcysteine

Approved, Investigational

Phase 3

616-91-1

12035

Interventional clinical trials:

(show top 50) (show all 191)

#	Name	Status	NCT ID	Phase	Drugs
1	Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis	Unknown status	NCT00265252	Phase 4	Alendronate
2	Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases	Completed	NCT00434447	Phase 4	Zoledronic acid
3	Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings	Completed	NCT01806766	Phase 4
4	A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients	Completed	NCT01345097	Phase 4
5	Ultra-Short Anatomic and Conventional Cementless Stems Cementless Stems in Patients Younger Than Fifty-Five Years Old	Completed	NCT02338596	Phase 4
6	Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study	Completed	NCT02139007	Phase 4	Alendronate
7	Management of Mandibular ORN: PENTO as Medical Treatment	Completed	NCT02368457	Phase 4	Pentoxifylline and Tocopherol
8	Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty	Completed	NCT02379663	Phase 4	Rivaroxaban;Enoxaparin
9	Benefit of Orthopedic Navigation in the ARThroplasty of the Hip	Completed	NCT01496300	Phase 4
10	Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI	Recruiting	NCT02893293	Phase 4	Ferumoxytol-enhanced magnetic resonance imaging
11	Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis	Recruiting	NCT02984228	Phase 4	Hyaluronic Acid
12	Prolonged Protection From Bone Disease in Multiple Myeloma	Recruiting	NCT02286830	Phase 4	Zoledronic acid
13	Optetrak Posterior Stabilized Versus Optetrak Hi-Flex	Withdrawn	NCT00808613	Phase 4
14	Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH)	Unknown status	NCT01613612	Phase 2, Phase 3
15	Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia	Unknown status	NCT01423747	Phase 3	VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
16	ALL-SCT BFM International- HSCT in Children and Adolescents With ALL	Unknown status	NCT01423500	Phase 3	VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
17	Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial	Completed	NCT00532220	Phase 3	Ibandronate IV;Placebo
18	Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head	Completed	NCT00939900	Phase 3	zoledronic acid (aclasta)
19	Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis	Completed	NCT00523341	Phase 3
20	Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial	Completed	NCT02181101	Phase 3	FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
21	Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone	Completed	NCT01924286	Phase 3	Prednisone;Placebo
22	N-Acetylcysteine in Patients With Sickle Cell Disease	Completed	NCT01849016	Phase 3	N-Acetylcysteine;Placebo
23	Aspirin in the Prevention of Collapse in Osteonecrosis of the Hip	Recruiting	NCT03405974	Phase 3	Aspirin;Placebo
24	Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head	Recruiting	NCT01529008	Phase 3	Core decompression/PREOB® implantation;Core decompression/placebo implantation
25	Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)	Recruiting	NCT03040778	Phase 3	Pentoxifylline;Placebo;Tocopherol
26	Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents	Recruiting	NCT02684708	Phase 3	cyclophosphamide, vincristine, prednisone, dacarbazine;cyclo, vcr, pred, dacarb,etop and doxo
27	Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks	Recruiting	NCT02051218	Phase 3	Denosumab (reduced dosing);Denosumab (standard dosing)
28	Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies	Recruiting	NCT03408652	Phase 3	denosumab
29	Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.	Recruiting	NCT02609828	Phase 3	Tanezumab
30	Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head	Active, not recruiting	NCT01892514	Phase 3
31	ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee	Active, not recruiting	NCT01458782	Phase 2, Phase 3
32	Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2)	Active, not recruiting	NCT01908751	Phase 3	Vitamin D;Vitamin D Placebo
33	Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement	Active, not recruiting	NCT00869206	Phase 3	zoledronic acid
34	Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.	Active, not recruiting	NCT02709486	Phase 3	Tanezumab;Tanezumab;Placebo
35	Study of Skeletal Response to Eliglustat in Patients With Gaucher Disease	Enrolling by invitation	NCT02536755	Phase 3	eliglustat GZ385660
36	Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw	Not yet recruiting	NCT03390777	Phase 2, Phase 3
37	Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis	Terminated	NCT02114489	Phase 3	ibandronate;Placebo
38	Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma	Terminated	NCT02739594	Phase 3	Ibandronate;Zoledronate
39	A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement	Terminated	NCT00208468	Phase 3
40	Osteonecrosis of the Hip and Bisphosphonate Treatment	Unknown status	NCT00781261	Phase 2	Zoledronic Acid;Placebo
41	MBCP Safety and Performance in the Osteonecrosis of Femur Head	Unknown status	NCT00289575	Phase 2
42	Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head	Completed	NCT00505219	Phase 2
43	PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells	Completed	NCT01700920	Phase 2
44	Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head	Completed	NCT02890537	Phase 2	Core decompression/PREOB® implantation;Core decompression/BMC implantation
45	Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty	Completed	NCT01622465	Phase 2
46	Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents	Completed	NCT00921557	Phase 2	Alendronate;Placebo
47	Shock Wave Therapy for Osteoporosis	Completed	NCT02630381	Phase 2
48	MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)	Completed	NCT00996801	Phase 2	MK-5442;Placebo to MK-5442;Alendronate Sodium;Vitamin D3;Calcium carbonate;Placebo to Alendronate
49	Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers	Completed	NCT01367288	Phase 2	Zometa + Neoadjuvant therapy;Neoadjuvant therapy
50	Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery	Completed	NCT00393848	Phase 2	Essential amino acid supplement;Ketoconazole;Placebo

Search NIH Clinical Center for Osteonecrosis

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Osteonecrosis cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Osteonecrosis:

	JACC
	PREOB

Embryonic/Adult Cultured Cells Related to Osteonecrosis:

Cultured cartilage (JACC PMIDs: 16233778 19393556 10738867 16226641 11284883 12043781 16233853 19802670 10679677

Cochrane evidence based reviews: osteonecrosis

Sources

Genetic Tests for Osteonecrosis

Sources

Anatomical Context for Osteonecrosis

The Foundational Model of Anatomy Ontology organs/tissues related to Osteonecrosis:

¹⁹

Bone

MalaCards organs/tissues related to Osteonecrosis:

⁴¹

Bone, Bone Marrow, Testes, Skin, Endothelial, Prostate, Kidney

Sources

Publications for Osteonecrosis

Articles related to Osteonecrosis:

(show top 50) (show all 1120)

#	Title	Authors	Year
1	Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. ( 29955628 )	George E.L....Saunders M.M.	2018
2	Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. ( 29360413 )	Sakamoto K....Horibe K.	2018
3	Comment on: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29799056 )	Toh C.L....Dutton A.	2018
4	Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review. ( 29977926 )	Sacco R....Blythe J.S.J.	2018
5	Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia: two and a half to fourteenA year follow-up. ( 29594456 )	Wang W....Gao F.	2018
6	Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. ( 29941400 )	Won A.M....Chambers M.	2018
7	Association of common comorbidities with osteonecrosis: a nationwide population-based case-control study in Denmark. ( 29439082 )	Dima A....Thomsen R.W.	2018
8	Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. ( 29211870 )	Uday S....HAPgler W.	2018
9	Short stem survival after osteonecrosis of the femoral head. ( 29396635 )	Schnurr C....Eysel P.	2018
10	Enhanced bone defect repairing effects in glucocorticoid-induced osteonecrosis of the femoral head using a porous nano-lithium-hydroxyapatite/gelatin microsphere/erythropoietin composite scaffold. ( 29369309 )	Li D....Kang P.	2018
11	Development of antiresorptive agent-related osteonecrosis of the jaw after dental implant removal: a case report. ( 29870295 )	Yamamoto S....Takenobu T.	2018
12	Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA-compliant meta-analysis of animal studies and clinical trials. ( 29362430 )	Li D....Kang P.	2018
13	Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. ( 29729428 )	Kuroshima S....Sawase T.	2018
14	Early removal of sequestrum in patients affected by medication-related osteonecrosis of the jaw. ( 29422306 )	Kharazmi M....Hallberg P.	2018
15	Machine learning to predict the occurrence of bisphosphonate-related osteonecrosis of the jaw associated with dental extraction: A preliminary report. ( 29698784 )	Kim D.W....Cha I.H.	2018
16	The biological basis for concentrated iliac crest aspirate to enhance core decompression in the treatment of osteonecrosis. ( 29435623 )	Goodman S.B.	2018
17	Th17 and IL-17 exhibit higher levels in osteonecrosis of the femoral head and have a positive correlation with severity of pain. ( 29952419 )	Zou D....Li J.	2018
18	Correction to : Hip osteonecrosis: stem cells for life or behead and arthroplasty? ( 29934718 )	Hernigou P....Hernigou J.	2018
19	Diving, Dysbaric Osteonecrosis ( 29493935 )	White T.C....Cooper J.S.	2018
20	Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. ( 29802059 )	Nisi M....Gabriele M.	2018
21	Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics. ( 29325851 )	De Bruyn L....Politis C.	2018
22	Recommendations for the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Systematic Review. ( 29747794 )	Aparecida Cariolatto F....Bonilauri Ferreira A.P.	2018
23	Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-NaA^ve Patient: A Comprehensive Review of the Literature. ( 29850569 )	Pimolbutr K....Fedele S.	2018
24	Pyogenic arthritis pyoderma gangrenosum and acne syndrome: A rare but important diagnosis for antibiotic-resistant erysipelas-like erythema and osteonecrosis. ( 29943877 )	Martini G....Di Palma A.	2018
25	Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223. ( 29861164 )	Herlofson B.B....Bruland A.9.S.	2018
26	Thrombophilia-Associated Factors in Patients with Spontaneous Osteonecrosis of the Knee. ( 29308659 )	Marom N....Hetsroni I.	2018
27	Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions. ( 29432652 )	McGowan K....Acton C.	2018
28	Accuracy of MRI diagnosis of early osteonecrosis of the femoral head: a meta-analysis and systematic review. ( 29973239 )	Zhang Y.Z....Zheng W.	2018
29	Comment on &quot;Nasolabial Flap Improves Healing in Medication-Related Osteonecrosis of the Jaw&quot; by Lemound etA al. ( 29902417 )	Myoken Y....Fujita Y.	2018
30	The association with xerostomia from sialadenitis and the jaw osteonecrosis in head and neck cancer population: a nationwide cohort study. ( 29725850 )	Huang Y.F....Chang C.T.	2018
31	Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis. ( 29289789 )	Messer J.G....Aguirre J.I.	2018
32	FGF2 and FAM201A affect the development of osteonecrosis of the femoral head after femoral neck fracture. ( 29382571 )	Huang G....Shi J.	2018
33	Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. ( 29408511 )	Elsayed R....Elsalanty M.E.	2018
34	Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. ( 29943905 )	Mogensen S.S....Frandsen T.L.	2018
35	Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? ( 29860712 )	Altundag K.	2018
36	Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5A years of experience. ( 29948937 )	Bernardi S....Cutilli T.	2018
37	A new 3D printed titanium metal trabecular bone reconstruction system for early osteonecrosis of the femoral head. ( 29952948 )	Zhang Y....Feng L.	2018
38	Vitamin D supplementation: Hypothetical effect on medication-related osteonecrosis of the jaw. ( 29857915 )	Lorenzo-Pouso A.I....Carballo J.	2018
39	The role of the subchondral layer in osteonecrosis of the femoral head: analysis based on HR-QCT in comparison to MRI findings. ( 29979104 )	Kolb A.R....Hofstaetter J.G.	2018
40	Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. ( 29713913 )	Voss P.J....Semper-Hogg W.	2018
41	High-energy extracorporeal shock wave therapy for nontraumatic osteonecrosis of the femoral head. ( 29394948 )	Xie K....Yan M.	2018
42	Auto-Fluorescence and Histopathologic Evaluation of Medication-Related Osteonecrosis of the Jaws: Perspectives for Treatment. ( 29944562 )	Giovannacci I....Meleti M.	2018
43	Authors' reply: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29796683 )	Chan B.H....Ang S.B.	2018
44	Extravascular Hydrophobic Surfaces, Fat Droplets, and the Connection With Decompression Illness: Spinal, Joint Pain, and Dysbaric Osteonecrosis. ( 29636703 )	Arieli R.	2018
45	Medication-related osteonecrosis of the jaw, osteoradionecrosis, and osteomyelitis: A comparative histopathological study. ( 29723337 )	De Antoni C.C....Cardoso C.L.	2018
46	The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. ( 29694412 )	Chiu W.Y....Tsai K.S.	2018
47	Duration of treatment with bisphosphonates at the time of osteonecrosis of the jaw onset in patients with rheumatoid arthritis. Review. ( 29325766 )	Compain H....Zwetyenga N.	2018
48	Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings. ( 29952657 )	Walton K....Tetradis S.	2018
49	Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care. ( 29932939 )	Hadaya D....Aghaloo T.L.	2018
50	New method of alloplastic reconstruction of the mandible after subtotal mandibulectomy for medication-related osteonecrosis of the jaw. ( 29751943 )	BrAouer C....Leonhardt H.	2018

Sources

Genes for Osteonecrosis

Genes related to Osteonecrosis (0 elite genes):

(show all 18)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	BMP2	Bone Morphogenetic Protein 2	Protein Coding	24.21	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	BGLAP	Bone Gamma-Carboxyglutamate Protein	Protein Coding	23.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	TNFSF11	TNF Superfamily Member 11	Protein Coding	23.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	TNFRSF11B	TNF Receptor Superfamily Member 11b	Protein Coding	23.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	23.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	SERPINE1	Serpin Family E Member 1	Protein Coding	23.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	RUNX2	Runt Related Transcription Factor 2	Protein Coding	22.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	F2	Coagulation Factor II, Thrombin	Protein Coding	22.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	22.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	COL2A1	Collagen Type II Alpha 1 Chain	Protein Coding	22.63	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	22.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	ACP5	Acid Phosphatase 5, Tartrate Resistant	Protein Coding	22.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	CYP2C8	Cytochrome P450 Family 2 Subfamily C Member 8	Protein Coding	22.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	FDPS	Farnesyl Diphosphate Synthase	Protein Coding	21.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	PTH	Parathyroid Hormone	Protein Coding	21.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	SERPINC1	Serpin Family C Member 1	Protein Coding	21.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4	Protein Coding	21.59	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	BMP7	Bone Morphogenetic Protein 7	Protein Coding	21.55	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Osteonecrosis

Sources

Expression for Osteonecrosis

Search GEO for disease gene expression data for Osteonecrosis.

Sources

Pathways for Osteonecrosis

Pathways related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 21)

#	Super pathways	Score	Top Affiliating Genes
1	Parathyroid hormone synthesis, secretion and action ³⁷	11.78	BGLAP PTH RUNX2 TNFSF11
2	Rheumatoid arthritis ³⁷	11.71	ACP5 TNFSF11 VEGFA
3	Statin Pathway - Generalized, Pharmacokinetics ⁶¹ Show member pathways Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics ⁶¹ Anti-diabetic Drug Repaglinide Pathway, Pharmacokinetics ⁶¹ Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics ⁶¹ Fluvastatin Pathway, Pharmacokinetics ⁶¹ Ibuprofen Pathway, Pharmacokinetics ⁶¹ Pravastatin Pathway, Pharmacokinetics ⁶¹ Rosiglitazone Pathway, Pharmacokinetics ⁶¹ Rosuvastatin Pathway, Pharmacokinetics ⁶¹	11.68	ABCB1 CYP2C8 CYP3A4
4	Imipramine/Desipramine Pathway, Pharmacokinetics ⁶¹ Show member pathways Amitriptyline and Nortriptyline Pathway, Pharmacokinetics ⁶¹ Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 ⁶⁶ Citalopram Pathway, Pharmacokinetics ⁶¹ Clomipramine Pathway, Pharmacokinetics ⁶¹ Clopidogrel Pathway, Pharmacokinetics ⁶¹ Clozapine Pathway, Pharmacokinetics ⁶¹ Colchicine Metabolic Pathway ¹ Lidocaine metabolism ¹ Olanzapine Pathway, Pharmacokinetics ⁶¹ Paroxetine Pathway, Pharmacokinetics ⁶¹ Proton Pump Inhibitor Pathway, Pharmacokinetics ⁶¹ Venlafaxine Pathway, Pharmacokinetics ⁶¹ Verapamil Pathway, Pharmacokinetics ⁶¹	11.63	ABCB1 CYP2C8 CYP3A4
5	Signaling by BMP ⁶⁶ Show member pathways BMP receptor signaling ¹ Bone Morphogenic Protein (BMP) Signalling and Regulation ¹	11.57	BMP2 BMP7 RUNX2
6	HIF-1-alpha transcription factor network ¹	11.51	ABCB1 SERPINE1 VEGFA
7	Gefitinib Pathway, Pharmacokinetics ⁶¹ Show member pathways Doxepin Pathway, Pharmacokinetics ⁶¹ Fluoxetine Pathway, Pharmacokinetics ⁶¹ Imatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶¹ Nevirapine Pathway, Pharmacokinetics ⁶¹ Pazopanib Pathway, Pharmacokinetics ⁶¹ Warfarin Pathway, Pharmacokinetics ⁶¹	11.48	ABCB1 CYP2C8 CYP3A4
8	Phenytoin Pathway, Pharmacokinetics ⁶¹ Show member pathways Atomoxetine Pathway, Pharmacokinetics ⁶¹ Carbamazepine Pathway, Pharmacokinetics ⁶¹ Cyclophosphamide Pathway, Pharmacokinetics ⁶¹ Sorafenib Pharmacokinetics ⁶¹	11.42	ABCB1 CYP2C8 CYP3A4
9	Irinotecan Pathway ¹ Show member pathways Irinotecan Pathway, Pharmacodynamics ⁶¹ Irinotecan Pathway, Pharmacokinetics ⁶¹ Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics ⁶¹	11.39	ABCB1 CYP2C8 CYP3A4
10	Endochondral Ossification ¹	11.37	BMP7 COL2A1 PTH RUNX2 VEGFA
11	Development_Hedgehog and PTH signaling pathways in bone and cartilage development ²²	11.15	BGLAP PTH RUNX2 TNFSF11
12	Erlotinib Pathway, Pharmacokinetics ⁶¹ Show member pathways Atazanavir Pathway, Pharmacokinetics/Pharmacodynamics ⁶¹ Dasatinib Pathway, Pharmacokinetics ⁶¹	10.99	ABCB1 CYP2C8 CYP3A4
13	Drug Induction of Bile Acid Pathway ¹	10.83	ABCB1 CYP3A4
14	Osteoclast Signaling ¹	10.78	ACP5 TNFRSF11B TNFSF11
15	Etoposide Pathway, Pharmacokinetics/Pharmacodynamics ⁶¹	10.77	ABCB1 CYP3A4
16	Warfarin Pathway, Pharmacodynamics ⁶¹	10.76	BGLAP F2
17	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	10.75	BGLAP CYP3A4 PTH RUNX2 TNFRSF11B TNFSF11
18	Sirolimus Pathway, Pharmacokinetics/Pharmacodynamics ⁶¹	10.72	ABCB1 CYP2C8 CYP3A4
19	Taxane Pathway, Pharmacokinetics ⁶¹	10.61	ABCB1 CYP2C8 CYP3A4
20	Vinka Alkaloid Pathway, Pharmacokinetics ⁶¹	10.55	ABCB1 CYP3A4
21	Osteoblast Signaling ¹	10.4	BGLAP PTH TNFRSF11B TNFSF11

Sources

GO Terms for Osteonecrosis

Cellular components related to Osteonecrosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.7	BGLAP BMP2 BMP7 COL2A1 F2 PTH
2	endoplasmic reticulum lumen	GO:0005788	9.46	BGLAP COL2A1 F2 SERPINC1
3	extracellular space	GO:0005615	9.36	BGLAP BMP2 BMP7 COL2A1 F2 PTH

Biological processes related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 33)

#	Name	GO ID	Score	Top Affiliating Genes
1	response to drug	GO:0042493	9.83	ABCB1 BGLAP MTHFR PTH TNFRSF11B
2	osteoblast differentiation	GO:0001649	9.82	BGLAP BMP2 RUNX2
3	BMP signaling pathway	GO:0030509	9.8	BMP2 BMP7 RUNX2
4	regulation of signaling receptor activity	GO:0010469	9.76	BMP2 BMP7 F2 PTH SERPINE1 TNFRSF11B
5	cartilage development	GO:0051216	9.75	BMP2 BMP7 COL2A1
6	positive regulation of osteoblast differentiation	GO:0045669	9.73	BMP2 BMP7 RUNX2
7	odontogenesis of dentin-containing tooth	GO:0042475	9.72	BMP2 BMP7 RUNX2
8	bone development	GO:0060348	9.71	BGLAP COL2A1 TNFSF11
9	osteoblast development	GO:0002076	9.66	BGLAP RUNX2
10	mammary gland alveolus development	GO:0060749	9.65	TNFSF11 VEGFA
11	regulation of osteoclast differentiation	GO:0045670	9.65	BGLAP TNFSF11
12	positive regulation of ossification	GO:0045778	9.65	BMP2 PTH
13	response to inorganic substance	GO:0010035	9.64	BGLAP TNFRSF11B
14	positive regulation of blood coagulation	GO:0030194	9.63	F2 SERPINE1
15	chondrocyte differentiation	GO:0002062	9.63	BMP2 COL2A1 RUNX2
16	regulation of blood coagulation	GO:0030193	9.62	F2 SERPINC1
17	oxidative demethylation	GO:0070989	9.62	CYP2C8 CYP3A4
18	embryonic skeletal joint morphogenesis	GO:0060272	9.61	BMP7 COL2A1
19	peptidyl-glutamic acid carboxylation	GO:0017187	9.61	BGLAP F2
20	negative regulation of fibrinolysis	GO:0051918	9.6	F2 SERPINE1
21	mesenchymal cell differentiation	GO:0048762	9.59	BMP2 BMP7
22	positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus	GO:1901522	9.58	BMP2 RUNX2
23	positive regulation of bone mineralization	GO:0030501	9.58	BMP2 BMP7 PTH
24	proteoglycan metabolic process	GO:0006029	9.57	BMP2 COL2A1
25	cellular response to BMP stimulus	GO:0071773	9.56	BMP2 BMP7 COL2A1 RUNX2
26	bone resorption	GO:0045453	9.54	ACP5 PTH TNFSF11
27	lipid hydroxylation	GO:0002933	9.52	CYP2C8 CYP3A4
28	regulation of odontogenesis of dentin-containing tooth	GO:0042487	9.51	BMP2 RUNX2
29	response to vitamin D	GO:0033280	9.5	BGLAP BMP7 PTH
30	mesenchyme development	GO:0060485	9.48	BMP2 BMP7
31	ossification	GO:0001503	9.43	BGLAP BMP2 BMP7 COL2A1 RUNX2 TNFSF11
32	skeletal system development	GO:0001501	9.17	BGLAP BMP2 BMP7 COL2A1 PTH RUNX2
33	positive regulation of transcription by RNA polymerase II	GO:0045944	10.04	BMP2 BMP7 PTH RUNX2 SERPINE1 TNFSF11

Molecular functions related to Osteonecrosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth factor activity	GO:0008083	9.56	BMP2 BMP7 F2 VEGFA
2	heparin binding	GO:0008201	9.46	BMP7 F2 SERPINC1 VEGFA
3	BMP receptor binding	GO:0070700	9.37	BMP2 BMP7
4	estrogen 16-alpha-hydroxylase activity	GO:0101020	9.32	CYP2C8 CYP3A4
5	cytokine activity	GO:0005125	9.02	BMP2 BMP7 TNFRSF11B TNFSF11 VEGFA
6	caffeine oxidase activity	GO:0034875	8.96	CYP2C8 CYP3A4

Sources

Sources for Osteonecrosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia